First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy.
Pim B van der MeerMarta MaschioLinda DirvenMartin J B TaphoornJohan A F Koekkoeknull nullPublished in: Epilepsia (2022)
In this study, it was demonstrated that LEV had a significantly better effectiveness (i.e., less ASM treatment failure for any reason or due to adverse effects) compared to EIASMs, supporting the current neuro-oncology guideline recommendations to avoid EIASMs in glioma patients.